A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis

Inclusion Criteria: * male or females 12 to \< 17 years of age * Have a confirmed diagnosis of plaque psoriasis * Negative pregnancy test * Group 1: Have plaque psoriasis with an IGA score of ≥ 2 (mild), with at least one lesion ) and up to 20% Body Surface Area (BSA) involvement not including psoriasis on the face and scalp * Group 2: Have plaque psoriasis with a IGA score of ≥ 2 (mild), with plaque psoriasis involving at least 10% and up to 20% Body Surface Area (BSA) not including psoriasis on the face and scalp Exclusion Criteria: * known allergy or intolerance to the study drug or other vitamin D3 analogs or any of its components * history of or active generalized guttate, pustular or erythrodermic exfoliative psoriasis * history or presence of contact dermatitis induced by a topical medicine or other serious skin condition that is not well controlled * Use topical treatments known to have beneficial effects on psoriasis * Use phototherapy, oral corticosteroids, oral retinoid, oral immunosuppressive/immunomodulate drugs, cytostatics, cyclosporine or methotrexate within 30 days prior to the first dose of study drug * Use any approved biologics for psoriasis within 30 days or 5 half-lives of the biologic before the first dose of study drug * Are treated with medications known to worsen psoriasis * Are taking an oral vitamin D * Are taking medications that affect calcium metabolism; * Subjects who have an average of three (3) QTcF measurements of \> 450 milliseconds as shown on the ECG (Group 2 only); * Have clinically significant abnormal calcium homeostasis parameters at Visit 1; * Have clinically significant liver or renal dysfunction * Have any other clinically significant laboratory abnormalities, co-morbidities or psychiatric conditions which that would place the subject at increased risk or would confound the primary or secondary objectives of the study; * Use of any investigational drugs or biologics and/or participated in any clinical trial within the last 60 days before the day of the first dose of study drug or are taking part in a non-medication study which, that would interfere with study compliance or outcome assessments; * Are pregnant or lactating females; * Have a known history of congenital or acquired immunodeficiency.